Rituximab adjunctive therapy for Burkitt's lymphoma
Phase 2
- Conditions
- Burkitt's lymphomaCancer
- Registration Number
- ISRCTN90296187
- Lead Sponsor
- niversity of Malawi College of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 220
Inclusion Criteria
1. Child <14 yrs of age with proven Burkitt's lymphoma (BL) or relapse or resistant BL
2. After full information, the guardians have given written informed consent, and the child if appropriate will be asked for assent
3. The guardian and patient will be willing and able to complete treatment and follow-up
Exclusion Criteria
1. Patients known to be allergic to trial medications
2. Patients or their guardians who do not consent
3. Pregnant and/or breastfeeding patients
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical Complete Remission rate at end of chemotherapy
- Secondary Outcome Measures
Name Time Method <br> 1. Clinical Complete Remission rate at one year post chemotherapy<br> 2. Severe adverse effects of rituximab<br>